Lung Cancer Trial, Recruiting NCT05363319 Sponsor: Regeneron Pharmaceuticals Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05363319
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be at least 18 years old when you start treatment with cemiplimab
  • You must have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed through a lab test of a tissue or cell sample
  • Your doctor must have already decided, as part of your normal care, to prescribe you a treatment plan that includes cemiplimab
  • You must be able to understand and fill out questionnaires related to the study
  • You must be able to give written consent to take part and must sign a consent form before any study activities begin

Who may not be able to join:

  • You have already received cemiplimab before joining the study
  • You have an autoimmune disease (where the immune system attacks the body) that is not well controlled
  • You have a medical reason why cemiplimab would not be safe for you, based on the official prescribing guidelines
  • You are currently taking part in another clinical study involving an experimental drug or procedure
  • You have memory, thinking, or other health difficulties that, in your doctor's opinion, would make it hard for you to complete the study questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
26 October 2022
Est. completion
30 October 2028

Where this trial is recruiting

🇦🇹 Austria 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇪🇸 Spain

Primary endpoints

Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov